Skip to main content

Elosulfase alfa Disease Interactions

There is 1 disease interaction with elosulfase alfa.

Major

Elosulfase alfa (applies to elosulfase alfa) pulmonary impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Fever, Sleep Apnea

Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions during elosulfase alfa therapy and require additional monitoring. Patients with acute febrile or respiratory illness at the time of elosulfase alfa infusion may be at higher risk of life-threatening complications from hypersensitivity reactions. Careful consideration should be given to the patient's clinical status before elosulfase alfa administration and delaying the elosulfase alfa infusion should be considered.

Antihistamine pretreatment may increase the risk of apneic episodes in patients with sleep apnea; evaluation of airway patency should be considered before starting therapy. Patients using supplemental oxygen or continuous positive airway pressure during sleep should have these treatments readily available during elosulfase alfa infusion in case of an acute reaction, or extreme drowsiness/sleep induced by antihistamine use.

References

  1. (2019) "Product Information. Vimizim (elosulfase alfa)." BioMarin Pharmaceutical Inc, SUPPL-17

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.